Vascular Solutions Inc. (VASC) Now Covered by Analysts at Needham & Company LLC
Needham & Company LLC began coverage on shares of Vascular Solutions Inc. (NASDAQ:VASC) in a report published on Thursday. The firm issued a buy rating and a $58.00 price objective on the medical device company’s stock.
Other research analysts have also issued research reports about the company. Sidoti lowered Vascular Solutions from a buy rating to a neutral rating and set a $47.00 target price on the stock. in a report on Tuesday, July 12th. Piper Jaffray Cos. raised their target price on Vascular Solutions from $45.00 to $49.00 and gave the company an overweight rating in a report on Tuesday, July 26th. TheStreet upgraded Vascular Solutions from a hold rating to a buy rating in a report on Monday, July 25th. Canaccord Genuity restated a buy rating on shares of Vascular Solutions in a report on Wednesday, August 10th. Finally, Zacks Investment Research upgraded Vascular Solutions from a hold rating to a buy rating and set a $52.00 target price on the stock in a report on Thursday, July 28th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $49.50.
Vascular Solutions (NASDAQ:VASC) traded down 1.37% during mid-day trading on Thursday, reaching $47.58. The company had a trading volume of 18,841 shares. The company has a market capitalization of $832.22 million, a price-to-earnings ratio of 88.11 and a beta of 0.54. Vascular Solutions has a 12-month low of $24.34 and a 12-month high of $50.72. The stock has a 50-day moving average of $48.50 and a 200 day moving average of $41.46.
Vascular Solutions (NASDAQ:VASC) last posted its earnings results on Monday, July 25th. The medical device company reported $0.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.03. Vascular Solutions had a return on equity of 16.32% and a net margin of 6.22%. The company had revenue of $41.20 million for the quarter, compared to analyst estimates of $41.40 million. During the same quarter last year, the company earned $0.29 earnings per share. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. On average, analysts expect that Vascular Solutions will post $1.24 EPS for the current year.
In related news, VP William Rutstein sold 10,011 shares of the stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of $46.26, for a total transaction of $463,108.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Howard Root sold 40,000 shares of the stock in a transaction that occurred on Wednesday, July 27th. The shares were sold at an average price of $45.11, for a total value of $1,804,400.00. Following the sale, the chief executive officer now directly owns 347,840 shares of the company’s stock, valued at $15,691,062.40. The disclosure for this sale can be found here. Corporate insiders own 6.90% of the company’s stock.
Several hedge funds have recently modified their holdings of VASC. First Mercantile Trust Co. increased its stake in Vascular Solutions by 129.4% in the third quarter. First Mercantile Trust Co. now owns 4,242 shares of the medical device company’s stock worth $205,000 after buying an additional 2,393 shares in the last quarter. Eqis Capital Management Inc. increased its stake in Vascular Solutions by 16.7% in the third quarter. Eqis Capital Management Inc. now owns 8,197 shares of the medical device company’s stock worth $395,000 after buying an additional 1,171 shares in the last quarter. Mason Street Advisors LLC purchased a new stake in Vascular Solutions during the second quarter worth about $141,000. Schwab Charles Investment Management Inc. increased its stake in Vascular Solutions by 2.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 59,446 shares of the medical device company’s stock worth $2,477,000 after buying an additional 1,194 shares in the last quarter. Finally, Stifel Financial Corp increased its stake in Vascular Solutions by 4.9% in the second quarter. Stifel Financial Corp now owns 170,869 shares of the medical device company’s stock worth $7,119,000 after buying an additional 7,987 shares in the last quarter. 82.08% of the stock is owned by institutional investors.
About Vascular Solutions
Vascular Solutions, Inc is a medical device company focused on bringing clinically advanced solutions to the market for treating coronary and peripheral vascular disease. The Company’s product line consists of devices and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein practices around the world.
Receive News & Ratings for Vascular Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.